Northwest Biotherapeutics (NWBO) Non-Current Debt (2010 - 2026)

Northwest Biotherapeutics' Non-Current Debt history runs 17 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 1.91% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $7.2 million, a 1.91% increase from a year earlier, with the FY2025 full-year figure at $12.3 million, down 0.51% from the prior year.
• Non-Current Debt fell to $7.2 million in Q1 2026 per NWBO's latest filing, from $12.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $20.7 million in Q3 2024 and bottomed at $5.9 million in Q3 2022.
• The 5-year median for Non-Current Debt is $12.3 million (2025), against an average of $12.6 million.
• Across the five-year window, Non-Current Debt slumped 76.18% in 2022 and jumped 239.04% in 2023, its largest moves.
• Year by year, Non-Current Debt stood at $6.0 million in 2022, then soared by 239.04% to $20.3 million in 2023, then tumbled by 38.97% to $12.4 million in 2024, then slipped by 0.51% to $12.3 million in 2025, then sank by 41.59% to $7.2 million in 2026.
• Per Business Quant, the three latest NWBO Non-Current Debt figures stand at $7.2 million (Q1 2026), $12.3 million (Q4 2025), and $7.2 million (Q3 2025).